The Wisconsin Alumni Research Foundation and FluGen have signed license agreements for a technology that has the potential to significantly improve the way influenza vaccines are manufactured.
The University of Wisconsin–Madison has received a $1.3 million grant from the Bill & Melinda Gates Foundation to support research aimed at understanding the molecular features that lead to influenza pandemics. UW–Madison will collaborate with Maryland-based Lentigen Corp. on the project.
Flu viruses with reduced sensitivity to the front-line drugs used to thwart and treat infection have been found in patients who were not treated with the drugs, according to an international team of researchers.
The MIT Club of Wisconsin, a state association for alumni of the Massachusetts Institute of Technology, is recognizing a University of Wisconsin–Madison influenza researcher and a bioscience spinoff company on Friday at its annual Technology Achievement Awards banquet.
A University of Wisconsin–Madison conference on Thursday, Oct. 12, "Surviving the Pandemic," is designed to help representatives from small- and medium-sized companies and nonprofit organizations assess their levels of preparedness and begin to develop their own company-specific plans.
A drug envisioned as a front-line defense for the next flu pandemic might have a genetic Achilles' heel that results in a drug-resistant influenza virus capable of infecting new human hosts, according to a study published Aug. 28 in the British medical journal The Lancet.
By solving a long-standing puzzle about how the influenza virus assembles its genetic contents into infectious particles that enable the virus to spread from cell to cell, scientists have opened a new gateway to a better understanding of one of the world's most virulent diseases.